Implementation of pharmacogenetics: The University of Maryland personalized anti‐platelet pharmacogenetics program

Despite a substantial evidence base, implementation of pharmacogenetics into routine patient care has been slow due to a number of non‐trivial practical barriers. We implemented a Personalized Anti‐platelet Pharmacogenetics Program (PAP3) for cardiac catheterization patients at the University of Maryland Medical Center and the Baltimore Veterans Administration Medical Center Patients' are offered CYP2C19 genetic testing, which is performed in our Clinical Laboratory Improvement Amendment (CLIA)‐certified Translational Genomics Laboratory. Results are returned within 5 hr along with clinical decision support that includes interpretation of results and prescribing recommendations for anti‐platelet therapy based on the Clinical Pharmacogenetics Implementation Consortium guidelines. Now with a working template for PAP3, implementation of other drug‐gene pairs is in process. Lessons learned as described in this article may prove useful to other medical centers as they implement pharmacogenetics into patient care, a critical step in the pathway to personalized and genomic medicine. © 2014 Wiley Periodicals, Inc.

[1]  Dan M. Roden,et al.  Implementing genomic medicine in the clinic: the future is here , 2013, Genetics in Medicine.

[2]  Alan R. Shuldiner,et al.  Pharmacogenomics of Anti-platelet Therapy: How much evidence is enough for clinical implementation? , 2013, Journal of Human Genetics.

[3]  S. Scott,et al.  Antiplatelet drug interactions with proton pump inhibitors , 2014, Expert opinion on drug metabolism & toxicology.

[4]  Sarah H. Stephens,et al.  Pharmacogenomics of Anti-platelet and Anti-coagulation Therapy , 2013, Current Cardiology Reports.

[5]  A. Bura,et al.  2 C 19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects , 2006 .

[6]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[7]  E. Antman,et al.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.

[8]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[9]  J. Mega,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[10]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.

[11]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[12]  Kristin A. Maloney,et al.  The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real‐World Implementation , 2013, Clinical pharmacology and therapeutics.

[13]  Laura Mauri,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.

[14]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[15]  S. Iturria,et al.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.

[16]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype , 2012, Clinical pharmacology and therapeutics.

[17]  Jeanette J McCarthy,et al.  Genomic Medicine: A Decade of Successes, Challenges, and Opportunities , 2013, Science Translational Medicine.

[18]  M. Relling,et al.  Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.

[19]  A. Beitelshees,et al.  Cost‐Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel , 2012, Pharmacotherapy.

[20]  T. Klein,et al.  Clopidogrel: A Case for Indication‐Specific Pharmacogenetics , 2012, Clinical pharmacology and therapeutics.

[21]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.

[22]  A. Bura,et al.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.

[23]  Deepak L. Bhatt,et al.  Antiplatelet therapy and proton pump inhibition: cause for concern? , 2012, Current opinion in cardiology.

[24]  E. Clayton,et al.  Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.

[25]  Julie A Johnson,et al.  Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. , 2013, Pharmacogenomics.

[26]  Xiang Ma,et al.  Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. , 2013, International journal of cardiology.

[27]  E. Rampersaud,et al.  Identification of Novel Candidate Genes for Type 2 Diabetes From a Genome-Wide Association Scan in the Old Order Amish , 2007, Diabetes.

[28]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[29]  R. Weinshilboum,et al.  Challenges in Implementing Genomic Medicine: The Mayo Clinic Center for Individualized Medicine , 2013, Clinical pharmacology and therapeutics.

[30]  J. O’Connell,et al.  A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection , 2008, Science.

[31]  L Gong,et al.  The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy , 2012, Clinical pharmacology and therapeutics.